Donald Mitema, MD
Transplant Surgery · Rochester, MNNPI 1053622142
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,329 of the $1,482 with a category attached, or 89.7%. 15 manufacturers reported payments, led by Pfizer at 24.8% of the total. Reporting peaked in 2022 at $390 and has fallen 54.1% since, to $179 in 2025. That places this record below the midpoint for transplant surgery clinicians in MN, where the typical reported total is $2,247.
Across 74 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$368
- Johnson & Johnson$166
- AstraZeneca$165
- Aurinia Pharma U.S., Inc.$139
- Boehringer Ingelheim$138
- Fresenius USA Marketing, Inc.$113
- plus $394 from 9 others
What the payments were for
- Food & beverage$1,32990%
- Education$15310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 19 | $368 |
| Johnson & Johnson | 8 | $166 |
| AstraZeneca | 9 | $165 |
| Aurinia Pharma U.S., Inc. | 6 | $139 |
| Boehringer Ingelheim | 2 | $138 |
| Fresenius USA Marketing, Inc. | 7 | $113 |
| Bayer | 5 | $92 |
| Akebia Therapeutics Inc | 5 | $92 |
| Vifor Pharma, Inc. | 2 | $38 |
| Travere Therapeutics, Inc. | 4 | $35 |
| Ardelyx, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Novartis | 1 | $31 |
| Nxstage Medical, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$119
How this compares
$1,482 in reported general payments places this provider in the 20th percentile of 21 transplant surgery providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 38 | $94,391 |
| FarxigaDapagliflozin Propanediol | 90 | $88,856 |
| OzempicSemaglutide | 65 | $67,337 |
| AuryxiaFerric Citrate | 34 | $54,258 |
| XphozahTenapanor Hcl | 16 | $44,637 |
| JardianceEmpagliflozin | 37 | $32,192 |
| LokelmaSodium Zirconium Cyclosilicate | 31 | $29,956 |
| EntrestoSacubitril/Valsartan | 19 | $15,885 |
| Lanthanum Carbonate | 15 | $15,505 |
| ProcritEpoetin Alfa | 18 | $13,222 |
| MounjaroTirzepatide | 12 | $11,657 |
| KerendiaFinerenone | 11 | $6,845 |
| Sevelamer Carbonate | 78 | $4,603 |
| Cinacalcet Hcl | 22 | $3,825 |
| Nifedipine ErNifedipine | 71 | $2,794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $165 | $118,812121 claims |
| Fresenius USA Marketing, Inc.Velphoro | $113 | $94,39138 claims |
| Akebia Therapeutics IncAuryxia | $92 | $54,25834 claims |
| Boehringer IngelheimJardiance | $138 | $32,19237 claims |
| NovartisEntresto | $31 | $15,88519 claims |
| Johnson & JohnsonProcrit | $166 | $13,22218 claims |
| BayerKerendia | $92 | $6,84511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 21 transplant surgery providers in Minnesota.
Other transplant surgery in Rochester
- Mark StegallRochester$46K
- Timucin TanerRochester$12K
- Mikel PrietoRochester$12K
- Julie HeimbachRochester$7K
- Randi RyanRochester$6K
- Patrick DeanRochester$6K
- Tayyab DiwanRochester$3K
- Patricia RebolledoRochester$3K
- Andrew MacdonaldRochester$2K
- Zhihao LiRochester$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.